GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.

Author: Daigal Gokinos
Country: Germany
Language: English (Spanish)
Genre: Health and Food
Published (Last): 24 June 2013
Pages: 186
PDF File Size: 11.44 Mb
ePub File Size: 6.59 Mb
ISBN: 666-4-90604-312-2
Downloads: 60454
Price: Free* [*Free Regsitration Required]
Uploader: Goltigor

Arixtra Monograph for Professionals –

Prevention of postoperative DVT and PE in patients undergoing hip-fracture, hip-replacement, or unformation surgery. Initial parenteral anticoagulants with established efficacy in patients with NSTE ACS include enoxaparin, heparin, bivalirudin only in patients managed with an early invasive strategyand fondaparinux.

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. Importance of informing patients that concomitant use of aspirin or other NSAIAs can increase risk of bleeding, and to discontinue use of these drugs whenever possible.

Several antithrombotic agents e. Importance of patients informing clinicians including dentists that they are receiving fondaparinux therapy before scheduling any invasive procedures.


Use with extreme caution in patients with an increased risk of hemorrhage e. Following a single 7. Usual duration of therapy is 5—9 days, although up to 10 days has been studied. A synthetic pentasaccharide for the prevention of deep- vein thrombosis.

Some packaging components e. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: Natural rubber-containing medical devices; user labeling.

Prevention of VTE in nonorthopedic surgical patients: Usual duration of therapy is 5—9 days, 1 3 4 5 6 although up to 11 days has been studied in clinical trials of orthopedic surgery. By clicking Subscribe, I agree to the Drugs. Anemia, fever, nausea, edema, constipation, rash, vomiting, insomnia, increased wound drainage, hypokalemia, urinary tract infection, dizziness, purpura, hypotension, confusion, bullous eruption, urinary retention, hematoma, major bleeding, diarrhea, dyspepsia, postoperative hemorrhage, headache.

Mylan Worldwide

Am J Health-Syst Pharm. If coadministration is essential, monitor patients closely History of serious hypersensitivity reaction e. Arixtra fondaparinux sodium injection prescribing information.

Extended thromboprophylaxis for up to 35 days is recommended in patients undergoing hip fracture surgery, 40 informatkon suggested for patients undergoing other major orthopedic procedures. A randomized double-blind trial. Distributed into milk in rats; not known whether distributed into human milk.


Administer by sub-Q injection into fatty tissue, alternating injection sites daily e. Postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: Used in patients undergoing PCI to prevent thrombus formation during the procedure; however, should not be used as prescriving sole anticoagulant to support PCI.

If fondaparinux therapy is to be continued after hospital discharge, importance of instructing patient on proper administration of the drug, including injection technique.

Prevention of VTE in orthopedic surgery patients: Importance of discontinuing fondaparinux and immediately contacting a preacribing if a serious allergic reaction e. Platelet function or global clotting function tests e. Lovenox enoxaparin sodium injection prescribing information. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous informatiin In healthy adults, distributes mainly in blood and only to a minor extent in extravascular fluid.

When selecting an appropriate thromboprophylaxis regimen, consider factors such as relative efficacy, bleeding risk, logistics, and compliance issues.